Oncology – Breast
Guideline | Reporting of surgically removed lymph nodes for breast tumors.
25 Oct, 2022 | 13:20h | UTC
Cohort Study | Systemic or vaginal hormone therapy after early breast cancer.
24 Oct, 2022 | 14:00h | UTCNews Release: Hormone replacement therapy doesn’t lead to breast cancer reoccurrence – Oxford University Press
Commentaries:
Hormone Replacement Therapy Won’t Raise Recurrence Rate for Breast Cancer Survivors – HealthDay
Post-trial follow-up | Adjuvant Olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer.
17 Oct, 2022 | 12:27h | UTCOriginal Study: Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
OS from #OlympiA now out on Annals. After 3.5y of f-up, pts receiving adjuvant olaparib derived a significant OS benefit (4y Δ 3.4%, 89.8% vs 86.4%). No increased risk of MDS/AML with olaparib. Important to test for BRCA in potentially eligible patients.https://t.co/ygkr0cOwF0 pic.twitter.com/bg4Y2yyXwZ
— Paolo Tarantino (@PTarantinoMD) October 11, 2022
Images under a Creative Commons Attribution (CC BY 4.0) license
Recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer.
14 Oct, 2022 | 14:12h | UTC
Cohort Study | Elevated C-reactive protein and subsequent patient-reported cognitive problems in older breast cancer survivors.
14 Oct, 2022 | 14:03h | UTC
Cohort Study | Association of long-term oncologic prognosis with minimal access breast surgery vs. conventional breast surgery.
13 Oct, 2022 | 13:38h | UTC
Commentary on Twitter
A single-center retrospective cohort study found that the long-term outcomes of minimal-access breast surgery are not significantly different from those of conventional #BreastSurgery in patients with stage 0-III #BreastCancer. https://t.co/SMQWCNSa4X
— JAMA Surgery (@JAMASurgery) October 6, 2022
RCT | Switch to fulvestrant and palbociclib in breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy.
7 Oct, 2022 | 14:12h | UTCSwitch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial – The Lancet Oncology (free for a limited period)
20-year follow-up of a RCT | Adjuvant Goserelin and Tamoxifen in premenopausal patients with breast cancer.
26 Sep, 2022 | 12:00h | UTCNews Release: Hormonal breast cancer treatment reduces long-term risk of recurrence – Karolinska Institutet
Commentary on Twitter
20-yr FU of the STOCKHOLM trial in pts with premenopausal #breastcancer reveals that those with genomic low-risk benefited most from tamoxifen & those with genomic high-risk from goserelin, with no benefit from combined goserelin-tamoxifen in either group: https://t.co/UDKo5huaFA
— NatureRevClinOncol (@NatRevClinOncol) August 4, 2022
M-A | Margin status and survival outcomes after breast cancer conservation surgery.
23 Sep, 2022 | 13:09h | UTCCommentary from the authors: Width of excision margins after breast conserving surgery for invasive breast cancer and distant recurrence and survival – The BMJ
News Release: Experts call for adequate tumour free margins in breast cancer surgery – BMJ Newsroom
Cohort Study | Fertility preservation procedures appear to be safe at the time of breast cancer diagnosis.
7 Sep, 2022 | 12:31h | UTCNews Release: Fertility preservation measures do not appear to increase the risk of breast cancer recurrence – Karolinska Institutet
Cohort Study | 5-year follow-up results suggest it is safe to de-escalate radiotherapy after primary chemotherapy in cT1–2N1 breast cancer.
31 Aug, 2022 | 11:45h | UTCDe-escalation of radiotherapy after primary chemotherapy in cT1–2N1 breast cancer (RAPCHEM; BOOG 2010–03): 5-year follow-up results of a Dutch, prospective, registry study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary on Twitter
At 5-year follow up in RAPCHEM, BOOG 2010–03 study of locoregional RT de-escalation in cT1-2N1 breast cancer, locoregional recurrence rates were 2.3%, 1.0% and 1.4% in low, intermediate and high risk groups, and therefore this approach was considered safe: https://t.co/4NkUwr4kxV
— NatureRevClinOncol (@NatRevClinOncol) August 15, 2022
RCT | Sacituzumab Govitecan in hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer.
29 Aug, 2022 | 12:05h | UTC
Triple negative breast cancer: pitfalls and progress.
26 Aug, 2022 | 13:02h | UTCTriple negative breast cancer: Pitfalls and progress – npj Breast Cancer
Consensus Recommendations | Standardizing pathologic evaluation of breast carcinoma after neoadjuvant chemotherapy.
23 Aug, 2022 | 12:52h | UTC
Spindle cell lesions of the breast: a diagnostic algorithm.
23 Aug, 2022 | 12:51h | UTC
Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies.
18 Aug, 2022 | 12:47h | UTCCommentaries:
Trastuzumab deruxtecan-related ILD/pneumonitis characterized – medwire News
ASCO Guideline Update | Chemotherapy and targeted therapy for human epidermal growth factor receptor 2–negative metastatic breast cancer that is either endocrine-pretreated or hormone receptor–negative.
17 Aug, 2022 | 14:17h | UTC
RCT | Adjuvant oral ibandronate does not improve outcomes in postmenopausal women with estrogen receptor–positive breast cancer.
16 Aug, 2022 | 13:15h | UTCDaily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor–Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: Adjuvant Ibandronate Not Beneficial for ER+ Breast Cancer – Cancer Therapy Advisor
Commentary on Twitter
New phase 3 trial of adjuvant bisphosphonates for ER+ eBC published on @JCO_ASCO.
1,116 patients randomized to ET +/- 3 years of ibandronate. No DFS benefit (HR 0.97, p=0.81). Eleven patients in the ibandronate arm developed osteonecrosis of the jaw.https://t.co/CxhZcTNLhU— Paolo Tarantino (@PTarantinoMD) April 21, 2022
RCT | Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast.
9 Aug, 2022 | 12:46h | UTCRadiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3–07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study – The Lancet (link to abstract – $ for full-text)
Cohort Study | Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer.
9 Aug, 2022 | 12:20h | UTC
Commentary on Twitter
Out on NPJ Breast a new report on #ERlowtumors. No difference in characteristics, pCR rates, RFS os OS compared with #TNBC. Patients with ER-low tumors should be treated as for TNBC. Also, important confounder to remember in HER2-low prognostic analyses.https://t.co/M1GF8eyYbT pic.twitter.com/CrLyUgyhUV
— Paolo Tarantino (@PTarantinoMD) July 11, 2022
RCT | Partial breast irradiation vs. whole breast irradiation for early breast cancer.
8 Aug, 2022 | 11:36h | UTCPartial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
M-A | Breast cancer recurrence after immediate and delayed postmastectomy breast reconstruction.
28 Jul, 2022 | 13:05h | UTC
Systematic Review | Taxane monotherapy regimens for treating recurrent epithelial ovarian cancer.
25 Jul, 2022 | 12:47h | UTC
RCT | Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer.
21 Jul, 2022 | 13:25h | UTCPembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Among patients with triple-negative breast cancer and high expression of PD-L1, pembrolizumab plus chemotherapy resulted in longer overall survival than chemotherapy alone. https://t.co/5urffgHdFb pic.twitter.com/2GlmJuYZJz
— NEJM (@NEJM) July 20, 2022
RCT | Oral Paclitaxel plus Encequidar vs. intravenous Paclitaxel in patients with metastatic breast cancer.
21 Jul, 2022 | 12:24h | UTC
Commentary on Twitter
Oral Paclitaxel is an alternative treatment option to every 3-week paclitaxel with more neutropenic serious infections and less incidence and severity of neuropathy for patients with advanced or mBChttps://t.co/wNrLfs2myN pic.twitter.com/l3aWGhEdwU
— K Pavithran (@drkpavithran) July 21, 2022